Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

This was the stock's second consecutive day of losses.

A specially curated, four-course meal will be on the menu this Valentine’s Day at The Abbey Resort. On Friday, Feb. 14, the ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

The stock's fall snapped a four-day winning streak.

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Learn more› By Erin Roberts and Ben Keough After considering new apps, we still think that Adobe Lightroom and Snapseed are the best choices for editing photos when you’re away from a desktop ...

Missouri woman with autism has a request for the Chiefs: she wants to be the team’s water girl Ye shocked at the Grammys red ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...